Edgewise Therapeutics (Edgewise Therapeutics) Total Assets : $553.81 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Total Assets?

Edgewise Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $553.81 Mil.

During the past 12 months, Edgewise Therapeutics's average Total Assets Growth Rate was 14.10% per year. During the past 3 years, the average Total Assets Growth Rate was 119.70% per year.

During the past 5 years, Edgewise Therapeutics's highest 3-Year average Total Assets Growth Rate was 157.50%. The lowest was 119.70%. And the median was 138.60%.

Total Assets is connected with ROA %. Edgewise Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -25.53%. Total Assets is also linked to Revenue through Asset Turnover. Edgewise Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Edgewise Therapeutics Total Assets Historical Data

The historical data trend for Edgewise Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Total Assets Chart

Edgewise Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

24.54

131.14

285.23

367.10

340.04

Edgewise Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial													346.40	330.63	311.36	340.04	553.81

Edgewise Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Edgewise Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	318.83	+	21.205
	=	340.04

Edgewise Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	534.941	+	18.865
	=	553.81

Edgewise Therapeutics (NAS:EWTX) Total Assets Explanation

Total Assets is connected with ROA %.

Edgewise Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-114.1	/	( (340.035	+	553.806)	/ 2 )
	=	-114.1	/	446.9205
	=	-25.53 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Edgewise Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (340.035	+	553.806)	/ 2 )
=	0	/	446.9205
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Edgewise Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3415 Colorado Avenue, Boulder, CO, USA, 80303

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017